Mylan N.V.

If you think about the difference between an 0375 and an 05, plus or minus 10 is another dose, right? And so it's closer to the lower dose, 0.25 or 0.45, right? So it can make a difference.

And so I did notice with the patches that they gave me that I didn't feel as good, and I even had some levels drawn which didn't seem like they were as good, and then the next time they filled it, it went back to the Mylan.

Thankfully I haven't been without it.

But I mean, I think that that's another thing to understand for women.

Not only did Pfizer get rid of a low growth and low margin division, they loaded up the combined company with a lot of debt.

I was initially very interested in this deal because after being the subject of congressional hearings related to the high cost of EpiPens, after Mylan kept increasing prices, Mylan's stock had been beaten down a lot.

But once I saw the final structure of the deal, I decided not to buy Viatress.

This was a good decision because Viatress is only up 23% since the November 2020 spinoff, and this is despite a 79% gain in the stock over the last year.

The other reason I stayed away is that low-margin generic drugs businesses are not all that attractive.

Mylan's key competitor back then, Teva Pharmaceuticals, was benefiting from its own patent-protected drug called Copaxone that was used to treat multiple sclerosis and at its peak generated over $4 billion in annual sales for Teva.

Teva also developed other branded drugs for migraines and other conditions.

In that context, this move by Viatris makes a lot of sense.

We can only cut the matrix patches.

So usually, the Sandos and the Mylan generic, um, Vyvelle Dot or Dotty, those patches are matrix patches, which means the medicine is spread evenly across the patch, so you could just simply cut it in half vertically, and then you have a little bit more play and some time to go find a patch, and you're not running panicked, um, when your 90-day supply is running out.

So that's one hack we've done.

A lot of folks have mo- have been moving to alternatives, so let's kind of talk through what some of those alternatives are, and then I would like a chance to say that I tried something new for all of you, and I'm really glad I did because I've changed my mind about a product.

So we talked about getting a double dose of the patch.

If you were at a 0.0375 dose, getting a 0.075 dose and cutting it in half, that would be a non-FDA approved option for, for matrix patches.

So things like the Sandoz or the Mylan, uh, Vyvelle Dot or Doty generics.

That would be an option.

Should I tell it to you real fast? I could actually have EpiPen money.

How? How could I have EpiPen money? Well, there is, um, there is a company called Mylan, and EpiPen is marketed and distributed by Viatris.

Viatris, I think it is, which they were formed with the Mylan merger in 2020, I think it was.

A couple, it was a couple years ago.

I think it's manufactured by Meridian, which is a subsidiary of Pfizer, but it's, it's part of Mylan.

And, uh, Mylan, I don't know much more about Mylan than this, that they sponsored our football field in high school in West Virginia.

And, uh, I don't know if they have an HQ, like a headquarters in West Virginia.

I th- I, I'm gu- I think, I think it is.

Should I tell it to you real fast? I could actually have EpiPen money.

How? How could I have EpiPen money? Well, there is, um, there is a company called Mylan, and EpiPen is marketed and distributed by Viatris.

Viatris, I think it is, which they were formed with the Mylan merger in 2020, I think it was, a couple, it was a couple years ago.

I think it's manufactured by Meridian, which is a subsidiary of Pfizer, but it's, it's part of Mylan.

And, uh, Mylan, I don't know much more about Mylan than this, that they sponsored our football field in high school in West Virginia.

And, uh, I don't know if they have an HQ, like a headquarters in West Virginia.

I th- I, I'm gu- I think, I think it is.

It's outside Pittsburgh.

Yeah, let's.

Yeah, so the company I'm gonna go over is Mylan.

They n- they now trade under the ticker...

Or the company, sorry.

the EpiPen came with a bunch of like generic drugs that they bought up from Merck right before the financial crisis.

I think it was in 2007.

So Pfizer would make the pens, and then Mylan would sell them.

So EpiPen controlled more than 95% of the market.

And generic companies spend years trying to figure out which of those patents they have to wait out and which ones they believe that they can challenge effectively in court.

And that's what Mylan's doing here is something called a paragraph four certification.

which in layman's terms, Mylan's told the FDA, we believe this patent is invalid or we believe the generic product does not infringe upon it.

The patent at issue, U.S. patent number 12,551,536, was issued in February of this year and is scheduled to run until October of 2038.

And it relates to the use of semaglutide for weight management.